The medical technology company Polarcool reports increased revenue in the first quarter compared with the same period last year. The operating loss was unchanged.Revenue rose to SEK 0.9 million (0.5).Operating profit/loss was SEK -3.8 million (-3.8). Profit/loss after tax was SEK -3.9 million (-3.8), and per share SEK -0.69 (-0.70). Cash and cash equivalents amounted to SEK 4.3 million (9.9).The company says that growth is driven by new agreements within international football and ice hockey, including an agreement with a top club in the UEFA Champions League. During the quarter, agreements were also signed with Rouen Hockey Elite 76 in France and Manchester Storm in the British EIHL.According to CEO Erik Andersson, Polarcool has also completed the MDSAP process, which enables applications for product approval for Polarcap in several countries, initially Canada. At the same time, the company continues regulatory processes in Canada and the USA ahead of a planned commercial launch in North America during 2026.Polarcool, SEK millionQ1-2026Q1-2025ChangeNet sales0.90.580.0%Operating profit/loss-3.8-3.8Net profit/loss-3.9-3.8Earnings per share, SEK-0.69-0.70Cash and cash equivalents4.39.9-56.6%